December 2018 - Clinical trial listings - geography, conditions, companies -

Clinical Trials for Lidoderm

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00266214	Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome	Terminated	Endo Pharmaceuticals	Phase 3	The purpose of this study is to evaluate the analgesic efficacy and safety of the lidocaine patch 5% compared to placebo in patients with moderate to severe pain associated with carpal tunnel syndrome.
NCT00414453	Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis	Terminated	Endo Pharmaceuticals	Phase 4	This study will determine whether treatment with an extended-release opioid or topical lidocaine is effective in relieving distal symmetric lower extremity burning pain associated with multiple sclerosis (MS). If treatment with topical lidocaine is efficacious, it will have important implications for understanding this chronic pain syndrome, which is widely assumed to be caused by central nervous system pathology.
NCT00414453	Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis	Terminated	University of Rochester	Phase 4	This study will determine whether treatment with an extended-release opioid or topical lidocaine is effective in relieving distal symmetric lower extremity burning pain associated with multiple sclerosis (MS). If treatment with topical lidocaine is efficacious, it will have important implications for understanding this chronic pain syndrome, which is widely assumed to be caused by central nervous system pathology.
NCT00589979	Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee	Completed	Endo Pharmaceuticals	Phase 2	Patients with knee pain due to Osteoarthritis (OA) experiencing sub-optimal pain relief from their current analgesic regimen will participate in a pilot clinical trial to evaluate the effectiveness and tolerability of the Lidoderm Patch compared with placebo in treating knee pain from OA.
NCT00903851	Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy	Completed	Endo Pharmaceuticals	Phase 4	Patients with Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy with dynamic allodynia of the lower extremities, patients with Type I or II diabetes and pain distal symmetric sensorimotor polyneuropathy with no dynamic allodynia of the lower extremities, or patients with idiopathic distal predominantly sensory neuropathy participated in a Phase IV clinical trial to assess the efficacy of lidocaine patches in treating painful diabetic neuropathy or idiopathic distal sensory neuropathy.
Trial ID	Title	Status	Sponsor	Phase	Summary